Pancreatic neuroendocrine tumor history and symptoms

Revision as of 19:00, 17 August 2015 by Shanshan Cen (talk | contribs)
Jump to navigation Jump to search

Pancreatic neuroendocrine tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic neuroendocrine tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic neuroendocrine tumor history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic neuroendocrine tumor history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic neuroendocrine tumor history and symptoms

CDC on Pancreatic neuroendocrine tumor history and symptoms

Pancreatic neuroendocrine tumor history and symptoms in the news

Blogs on Pancreatic neuroendocrine tumor history and symptoms

Directions to Hospitals Treating Pancreatic neuroendocrine tumor

Risk calculators and risk factors for Pancreatic neuroendocrine tumor history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Staging

The 2010 WHO classification of tumors of the digestive system grades all the neuroendocrine tumors into three categories, based on their degree of cellular differentiation (from well-differentiated "NET G1" through to poorly-differentiated "NET G3"). The NCCN recommends use of the same AJCC-UICC staging system as pancreatic adenocarcinoma. Using this scheme, the stage by stage outcomes for PanNETs are dissimilar to pancreatic exocrine cancers.[1] A different TNM system for PanNETs has been proposed by The European Neuroendocrine Tumor Society.

References

  1. National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) Incidence and Mortality [1]